通用名称

serdexmethylphenidate/dexmethylphenidate

儿科标签批准日期

2021/3/2 0:00:00

特定指示/秒

Attention Deficit Hyperactivity Disorder in pediatric patients 6 to 17 years

标签更改摘要

- Safety and effectiveness have been established in pediatric patients ages 6 to 17 years for the treatment of ADHD. - Use in patients 6 to 12 years is supported by a randomized, double-blind, placebo-controlled, parallel group trial in 155 pediatric patients with ADHD and a 12-month open-label long term safety trial in 238 patients. - Use in pediatric patients 13 to 17 years is supported by additional pharmacokinetics analysis showing similar plasma concentration-time profiles of dexmethylphenidate in adolescents and adults after administration of the same dose of AZSTARYS. - The long-term efficacy of methylphenidate in pediatric patients has not been established. - Safety and effectiveness in pediatric patients less than 6 years have not been established. - Information on dosing, adverse reactions, PK parameters, and clinical trials. - New active ingredient and new combination.

治疗类别

ADHD

立法类型

PREA Only

产品说明书链接

书号

N/A

研究年龄

N/A

学习类型

N/A

研究设计

N/A

登记的患者

N/A

患者分析

N/A

中心的数量

N/A

国家数量

N/A

西班牙裔拉美裔/拉丁裔总计

N/A

非西班牙裔/非拉丁裔总人数

N/A

总数#种族不明

N/A

亚裔学生总数

N/A

黑人总数

N/A

白人总数

N/A

夏威夷或太平洋岛民总数

N/A

美洲印第安人/阿拉斯加本地人总数

N/A

其他种族总计

N/A

未知种族总数

N/A

国家

N/A